Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988;26(2):139-44.
doi: 10.1007/BF00205607.

Role of proliferation in LAK cell development

Affiliations

Role of proliferation in LAK cell development

F J Ramsdell et al. Cancer Immunol Immunother. 1988.

Abstract

Lymphokine-activated killer (LAK) cell activity may be largely the result of activation and/or expansion of peripheral blood natural killer cells by culture with interleukin-2 (IL-2). We have examined the role of proliferation in LAK cell development by either inhibiting or enhancing the proliferative potential of peripheral blood lymphocytes. Inhibition of proliferation was accomplished using irradiation, mitomycin C, or the iron chelator deferoxamine. For each of these agents, a dose-dependent inhibition of proliferation was observed. At doses of inhibitor which nearly completely blocked thymidine uptake, the development of LAK activity was only partially impaired. The mitogenic lectins phytohemagglutinin (PHA) and concanavalin A (Con A) augmented the proliferative response of peripheral blood lymphocytes to IL-2. However, augmentation by PHA, but not Con A, consistently resulted in a decrease in LAK activity. This inhibition of LAK activity by PHA did not appear to be due to inhibition of the effector cell, nor to preferential expansion of irrelevant cells. These data suggests that not all LAK activity is dependent on proliferation, and that high levels of proliferation in the presence of IL-2 do not necessarily lead to LAK activity.

PubMed Disclaimer

References

    1. Damle NK, Doyle LV, Bradley EC. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol. 1986;137:2814. - PubMed
    1. D'Amore P, Golub SH. Suppression of human NK cell cytotoxicity by an MLC-generated cell population. J Immunol. 1985;134:272. - PubMed
    1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. - DOI - PMC - PubMed
    1. Grimm EA, Ramsey KM, Mazumder A, Wilson A, Djeu DJ, Rosenberg SA. Lymphokine-activated killer phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes and natural killer cells. J Exp Med. 1983;157:884. - PMC - PubMed
    1. Harel-Bellan A, Bertoglio J, Quillet A, Marchoil C, Wakasugi H, Mishall Z, Frudelizi D. Interleukin 2 (IL-2) upregulates its own receptor on a subset of human peripheral blood lymphocytes and triggers their proliferation. J Immunol. 1986;136:2463. - PubMed

Publication types

MeSH terms

LinkOut - more resources